Catalyst Event
Novartis AG (NVS) · Earnings Release
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
Q1 2026 earnings and revenue missed analyst expectations on April 28, 2026. Net sales were $13.1B (-1% reported, -5% constant currency) and core EPS was $1.99 (-13% reported), primarily due to US generic competition for the drug Entresto. The stock price declined following the announcement.
Korean Translation
2026년 4월 28일 발표된 1분기 실적 및 매출이 시장 예상치를 하회함. 미국 내 심부전 치료제 엔트레스토(Entresto)의 제네릭 경쟁 심화로 순매출은 131억 달러(-1%, 고정환율 기준 -5%), 핵심 EPS는 1.99달러(-13%)를 기록함. 발표 후 주가는 하락함.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon's Q1 2026 earnings release is scheduled for June 4, 2026, with analysts forecasting weak results following previous guidance. Earnings releases typically result in a >5% price impact, justifying a Medium importance, scheduled.
6/4/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time is scheduled to release its Q1 2026 financial results before market open on May 5, 2026. Importance is Medium as earnings releases typically result in price movements exceeding 5%, scheduled.
5/5/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled
4/30/2026, 12:00:00 AM